Published in Shock on August 09, 2017
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004) 2.64
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A (2008) 2.21
Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction. Circulation (2012) 2.12
GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med (2005) 2.05
On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol (2003) 1.77
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J (2002) 1.73
Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3beta inhibition. Crit Care Med (2006) 1.66
Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock (2009) 1.60
Peptidoglycan of Staphylococcus aureus causes inflammation and organ injury in the rat. Crit Care Med (2004) 1.57
Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock. Crit Care Med (2006) 1.54
Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol (2007) 1.53
Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury. Int J Cardiol (2011) 1.52
Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. Intensive Care Med (2003) 1.52
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol (2004) 1.50
Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. Lab Invest (2008) 1.49
Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat. Crit Care Med (2002) 1.49
Refinement of animal models of sepsis and septic shock. Shock (2015) 1.48
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med (2004) 1.48
Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol (2002) 1.47
Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. Br J Pharmacol (2005) 1.45
Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res (2005) 1.41
Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther (2004) 1.39
Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int (2013) 1.37
The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS (2007) 1.34
The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol (2002) 1.29
Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int (2004) 1.26
Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock (2007) 1.23
Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice. J Clin Invest (2004) 1.17
Dexamethasone ameliorates renal ischemia-reperfusion injury. J Am Soc Nephrol (2009) 1.17
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med (2006) 1.16
GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int (2003) 1.16
PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int (2009) 1.15
Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury. Kidney Int (2002) 1.15
Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med (2006) 1.14
Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock (2004) 1.12
High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock (2004) 1.12
Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother (2010) 1.11
The NLRP3 Inflammasome as a novel player of the intercellular crosstalk in metabolic disorders. Mediators Inflamm (2013) 1.11
Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain. J Neurosci (2003) 1.11
Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. Am J Respir Crit Care Med (2010) 1.10
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics (2007) 1.09
Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am J Respir Crit Care Med (2007) 1.09
Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock (2003) 1.09
The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. Shock (2004) 1.09
Role of induced nitric oxide in the initiation of the inflammatory response after postischemic injury. Shock (2002) 1.08
Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock (2006) 1.08
Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol (2003) 1.07
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol (2005) 1.06
Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol (2006) 1.06
Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14. Med Sci Monit (2002) 1.06
Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance. PLoS One (2009) 1.05
Glycogen synthase kinase-3beta inhibition attenuates asthma in mice. Am J Respir Crit Care Med (2007) 1.05
Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol (2003) 1.05
Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes (2008) 1.04
Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum (2003) 1.04
Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol (2006) 1.04
Junctional adhesion molecule-C mediates leukocyte infiltration in response to ischemia reperfusion injury. Arterioscler Thromb Vasc Biol (2009) 1.03
Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther (2006) 1.03
Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care (2011) 1.03
Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int (2006) 1.02
Inhibitors of NADPH oxidase reduce the organ injury in hemorrhagic shock. Shock (2005) 1.02
Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol (2010) 1.01
Glycogen synthase kinase-3beta inhibition attenuates the development of ischaemia/reperfusion injury of the gut. Intensive Care Med (2007) 1.00
Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: an in vivo study. Eur J Pharmacol (2009) 0.98
Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther (2004) 0.98
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. Intensive Care Med (2004) 0.98
Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin. Crit Care Med (2004) 0.98
Substance P increases neutrophil adhesion to human umbilical vein endothelial cells. Br J Pharmacol (2003) 0.97
Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure. J Infect Dis (2010) 0.97
Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther (2010) 0.97
Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. Dis Model Mech (2012) 0.97
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Malar J (2013) 0.96
Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol (2002) 0.96
Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit (2002) 0.96
Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock (2008) 0.96
TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. Proc Natl Acad Sci U S A (2013) 0.95
Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum (2005) 0.95
Peptidoglycan--an endotoxin in its own right? Shock (2006) 0.95
SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med (2009) 0.95
Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation. Shock (2006) 0.95
Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. FASEB J (2006) 0.94
A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol Med (2011) 0.94
Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol (2004) 0.93
Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury. J Pharmacol Exp Ther (2008) 0.93
Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol Pharmacol (2008) 0.93
The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. J Pharmacol Exp Ther (2005) 0.93